Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the local directory fallback.
Local D1 index available.
Filters: Condition: Marginal Zone B Cell Lymphoma) Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Acquired Bone Marrow Failure Syndromes, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Follicular Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, High Risk Anemia, Juvenile Myelomonocytic Leukemia, Lymphoblastic Lymphoma, Lymphoma, Lymphoplasmacytic Lymphoma, MRD Positive Leukemia, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Multiple Myeloma, Myelodysplasia, Myelofibrosis, Myeloproliferative Neoplasms, Natural Killer Cell Malignancies, Plasma Cell Leukemia, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
Interventions
HSCT with Non-TBI Regimen, HSCT with TBI Regimen
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced May 21, 2026, 12:56 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Multiple Myeloma, Myelodysplasia, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Leukemia, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Cyclophosphamide, Cyclosporine A, Fludarabine, Mycophenylate mofetil, Total Body Irradiation, Umbilical cord blood
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Follicular Lymphoma, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Follicular Lymphoma, Grade 1, Lymphoma, Marginal Zone B Cell Lymphoma, Marginal Zone Lymphoma
Interventions
Rituximab, Umbralisib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 16, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, Bone Marrow Failure Syndromes, Burkitt's Lymphoma, Chronic Myelogenous Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large-cell Lymphoma, Leukemia or MDS in Aplasia, Lymphoplasmacytic Lymphoma, MRD Positive Leukemia, Mantle-cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasms/Myelofibrosis, Natural Killer Cell Malignancies, Plasma Cell Leukemia, Prolymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Relapsed Multiple Myeloma, Relapsed Small Lymphocytic Lymphoma, Relapsed T-Cell Lymphoma
Interventions
ATG, Cyclophosphamide, Fludarabine, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced May 19, 2026, 7:28 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL), Marginal Zone B Cell Lymphoma, Small Lymphocytic Lymphoma (SLL)
Interventions
ME-401, Rituximab, Zanubrutinib
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
23
States / cities
Tucson, Arizona • Corona, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced May 5, 2026, 7:00 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Follicular Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, MALT Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Dexamethasone, Lenalidomide, Rituximab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Apr 30, 2026, 12:12 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large-cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Natural Killer Cell Malignancies, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma, Undifferentiated Leukemia
Interventions
Infusion of Treg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced May 5, 2026, 3:17 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Any T-cell Malignancy, Burkett's Lymphoma, CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Primary Lymphoma of the Central Nervous System, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced May 20, 2026, 12:21 AM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, Chronic Myeloproliferative Disease, Follicular Lymphoma, Hematologic Malignancy, High Grade Non-Hodgkin's Lymphoma, Large Cell Non-Hodgkin's Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-cell Lymphoma, Prolymphocytic Lymphoma, Small Lymphocytic Lymphoma
Interventions
CD3+ Teff cells, Cyclophosphamide, Fludarabine, Total body irradiation, Treg cells, Umbilical cord blood transplantation
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced May 5, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Lymphoma, Follicular, Malignant Lymphoma - Lymphoplasmacytic, Mantle Cell Lymphoma Recurrent, Marginal Zone B-Cell Lymphoma, Small Lymphocytic Lymphoma, T-Cell Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Doxycycline
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced May 16, 2026, 5:58 PM EDT